Panobinostat for the treatment of multiple myeloma
Mené sur 768 patients atteints d'un myélome multiple récidivant et/ou réfractaire, cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de panobinostat à un traitement combinant bortézomib et dexaméthasone
In 1998, thalidomide was shown to be effective in patients with advanced refractory multiple myeloma, astonishing almost all experts in the specialty. Part of the bewilderment was related to the fact that the drug was a notorious teratogen that had simply refused to be abandoned. But it was also because we knew almost nothing about its true mechanism of action. The history of thalidomide is a classic bedside-to-bench story that started in the 1960s, and that continues to this day. At least now w ...
The Lancet Oncology , commentaire, 2013